CoChat

Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis

Open access
Shi, Yu-Qi, Zhou, Xiao-Chong, Du, Peng, Yin, Min-Yue, Xu, Lan, Chen, Wen-Jie, Xu, Chun-Fang · 2020 · Medicine

The DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Background: Increased risk and cancer-related mortality is observed in pancreatic cancer (PC) patients with diabetes mellitus (DM). Whether using metformin as glucose-lowering therapy can result in survival benefit in this group of patients is still unclear. Methods: A meta-analysis of 21 studies that including 38,772 patients was performed to investigate the association between metformin and overall survival in patients with PC and concurrent DM. Results: A significant survival benefit was observed in metformin treatment group compared with non-metformin group (hazard ratio [HR] = 0.83, 95% confidence interval [CI]: 0.74–0.91). These associations were observed in both subgroups of Asian countries (HR = 0.69, 95% CI: 0.60–0.79) and Western countries (HR = 0.86, 95% CI: 0.76–0.95), the former was more obvious. Survival benefit was gained for patients at early stage (HR = 0.75, 95% CI: 0.64–0.85) and mixed stage (HR = 0.81, 95% CI: 0.70–0.91), but not for patients at advanced stage (HR = 0.99, 95% CI: 0.74–1.24). Similarly, survival benefit was also observed in patients receiving surgery (HR = 0.82, 95% CI: 0.69–0.94) and comprehensive treatment (HR = 0.85, 95% CI: 0.77–0.93), but not in chemotherapy group (HR = 0.99, 95% CI: 0.67–1.30). No obvious benefit was suggested when pooled by time-varying COX model (HR = 0.94, 95% CI: 0.86–1.03). Conclusions: These results suggest that metformin is associated with survival benefit in patients with PC and concurrent DM. Further randomized controlled trials and prospective studies with larger sample sizes are required to confirm our findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000021687

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Literature screening process.
Figure 1 Literature screening process.CC BY-NC · PubMed Central
Figure 2 Forest plot showed the association between metformin and OS for pancreatic cancer. Random-effect model was used. For each study, the estimates of HR and 95% CI were plotted with a box and a horizontal line. Closed diamond indicates pooled HR and 95% CI. CI = confidence interval, HR = hazard ratio, OS = overall survival.
Figure 2 Forest plot showed the association between metformin and OS for pancreatic cancer. Random-effect model was used. For each study, the estimates of HR and 95% CI were plotted with a box and a horizontal line. Closed diamond indicates pooled HR and 95% CI. CI = confidence interval, HR = hazard ratio, OS = overall survival.CC BY-NC · PubMed Central
Figure 3 (A and B) Begg Funnel plot and Egger linear regression test for BMI at diagnosis group studies. (A: Begg Funnel plot, B: Egger linear regression). BMI = body mass index.
Figure 3 (A and B) Begg Funnel plot and Egger linear regression test for BMI at diagnosis group studies. (A: Begg Funnel plot, B: Egger linear regression). BMI = body mass index.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 49

Metadata

Authors
Shi, Y.-Q., Zhou, X.-C., Du, P., Yin, M.-Y., Xu, L., Chen, W.-J., & Xu, C.-F.
Affiliations
  • Department of Gastroenterology, the First Affiliated Hospital of Soochow University
  • Soochow University
  • First Affiliated Hospital of Soochow University (CN)
  • Soochow University (CN)
  • The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Venue
Medicine
Published
2020-09-11
Volume
99
Issue
37
Pages
e21687
ISSN
  • 0025-7974 (ISSN-L)
  • 1536-5964
OpenAlex
W3086743075
Cited by
43
References
44
Citations by year
2026: 1 · 2025: 2 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 10
FWCI
0.77
Type
journal article
Language
en
Open access
Locations
  • Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Jiangsu Provincial Key Research and Development Program (BE2018659)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
metformin, pancreatic cancer, diabetes mellitus, overall survival, glucose-lowering therapy, cancer mortality, tumor stage, surgical treatment, chemotherapy, Asian patients
MeSH terms
Aged, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Pancreatic Neoplasms, Survival Rate, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1097/md.0000000000021687
The paper
Shi, Y.-Q., Zhou, X.-C., Du, P., Yin, M.-Y., Xu, L., Chen, W.-J., & Xu, C.-F. (2020). Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000021687

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.